Research programme: inflammation therapy - GeneCare Research/SCYNEXIS
Latest Information Update: 21 Mar 2007
At a glance
- Originator GeneCare Research Institute; SCYNEXIS Europe
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 17 Dec 2003 Preclinical trials in Inflammation in Europe (unspecified route)
- 17 Dec 2003 Preclinical trials in Inflammation in Japan (unspecified route)